Development of a Neutralizing Antibody Assay to support Clinical Trials

Frontage supported a Sponsor that required development of a Neutralizing Antibody (NAB) method for an antibody drug that interrupts a Ligand: Receptor interaction.Previous attempts to develop a Cell-Based NAB had been unsuccessful and current attempts to develop a Competitive Ligand Binding assay were also having difficulty with method sensitivity, reproducibility and drug tolerance. Pipeline progression for this asset was halted until these issues could be resolved.

Thank you for registering!

You now have the option of downloading the resource or viewing the web version below.